Latest Patents

Patents imply intellectual property and it has a $ value that can be associated depending on the field and type of patent that is allocated. Patents also increase the enterprise value of the company and help prevent copy-cats from copying the idea without having royalt payments or licencing deals. We like it when companies get patents awarded!. To protect IP companies aggressively file provisional patents even before they have a working product. The below table provides a way to look at what has been done by companies and use this as a factor to make investment decisions.

     
Title Filing Date Publication Date Grant Date
Bicyclic peptide ligands specific for mt1-mmp 2021-7-22 2022-1-27
Phage circularization assay 2020-10-02 2022-9-09
Modulation of structured polypeptide specificity 2020-6-11 2021-4-29
CD 38-specific bicyclic peptide ligands 2020-1-15 2021-11-02
CAIX-specific bicyclic peptide ligands 2020-1-15 2021-9-10
Integrin alphavbeta 3 specific bicyclic peptide ligands 2020-1-15 2021-11-05
PD-L1 specific bicyclic peptide ligands 2019-12-23 2021-8-13
Compounds for treating cancer 2019-12-16 2020-7-09
MT1-MMP specific bicyclic peptide ligands 2019-12-13 2021-10-19
IL-17 specific bicyclic peptide ligands 2019-12-13 2021-10-01
FAP alpha specific bicyclic peptide ligands 2019-12-13 2021-10-15
PSMA-specific bicyclic peptide ligands 2019-12-13 2021-10-15
Peptide ligands for binding EphA2 2019-6-18 2021-3-30
Ligands and methods of selecting binding targets for the ligands 2019-5-29 2021-3-19
Polypeptide ligands specific for plasma kallikrein 2019-1-03 2021-1-19 2021-1-19
Bicyclic peptide ligands specific for EPHA2 2018-12-19 2020-9-25
Bicycle peptide ligands specific for pd-l1 2018-1-15 2018-2-28
Bicyclic peptide ligands specific for CD38 2018-1-15 2018-2-28
Bicycle peptide ligands specific for caix 2018-1-15 2018-2-28
Bicycle peptide ligands specific for intergrin avb3 2018-1-15 2018-2-28
Bicyclic peptide ligands specific for EphA2 2017-12-19 2018-1-31
Methods for treating cancer 2017-11-27 2019-10-15 2019-10-15
Bicycle peptide ligands specific for EphA2 2017-9-27 2017-11-08
Interaction with multiple sites 2017-9-21 2017-11-08
Peptide derivatives having novel linkage structures 2017-8-23 2017-10-04
Modification of polypeptides 2017-8-23 2017-10-04
Peptide ligands for binding to Mt1-Mmp 2017-8-23 2017-10-04
Bicyclic peptide ligands specific for nectin-4 2017-8-08 2017-9-20
Bicyclic peptide ligands specific for CD137 2017-8-04 2017-9-20
Bicyclic peptide ligands specific for PD-L1 2017-8-04 2017-9-20
Bicyclic peptide ligand drug conjugates 2017-6-29 2017-8-16
Ligands and methods of selecting binding targets for such 2017-5-26 2017-7-12
Bicyclic peptide ligands specific for EphA2 2017-5-15 2017-6-28
Bicyclic peptide-toxin conjugates specific for mt1-mmp 2017-5-04 2017-11-09
Modification of polypeptides 2017-4-24 2017-6-07
Bicycle peptide ligands specific for CD38 2017-3-29 2017-5-10
Bicyclic peptide ligands specific for integrin AVB3 2017-2-03 2017-3-22
Bicyclic peptide ligands specific for CD38 2017-2-03 2017-3-22
Bicyclic peptide liglands specific for caix 2017-1-26 2017-3-15
Peptides derivatives 2017-1-18 2017-7-19
Stabilized peptide derivatives 2017-1-18 2017-7-19
Bicycle peptide ligands specific for EphA3 2017-1-05 2017-2-22
Peptide ligands for binding to MT1-MMP 2016-12-23 2017-2-08
Peptide derivatives having novel linkage structures 2016-12-23 2017-2-08
Modification of polypeptides 2016-12-23 2017-2-08
Bicyclic peptide ligands specific for PSMA 2016-12-22 2017-2-08
Bicyclic peptide ligands specific for TGFBETA 2016-12-19 2017-2-01
Bicycle peptide ligands specific for VEGF 2016-12-19 2017-2-01
Bicyclic peptide ligands specific for cathepsin G 2016-12-19 2017-2-01
Bicyclic peptide ligands specific for fapalpha 2016-12-19 2017-2-01
Bicycle peptide ligands specific for TNFALPHA 2016-12-19 2017-2-01
Bicycle peptide ligands specific for MMP9 2016-12-19 2017-2-01
Bicycle peptide ligands specific for KLK7 2016-12-14 2017-1-25
Bicycle peptide ligands specific for klk5 2016-12-14 2017-1-25
Bicycle peptide ligands specific for IL-17 2016-12-14 2017-1-25
Bicycle peptide ligands specific for IL-9 2016-12-14 2017-1-25
Bicyclic peptide 2016-12-12 2017-1-25
Bicycle peptide ligands specific for hsp90 2016-12-08 2017-1-25
Bicycle peptide ligands specific for chymase 2016-12-07 2017-1-18
Bicycle peptide ligands specific for cathepsin s 2016-12-02 2017-1-18
Bicycle peptide ligands specific for neutrophil elastase 2016-11-30 2017-1-11
Peptide libraries 2016-11-17 2017-3-09
Modulation of structured polypeptide specificity 2016-8-08 2017-5-26
Modification of polypeptides 2015-9-10 2016-2-04
Novel polypeptides 2015-8-27 2015-10-14
Multispecific peptides 2015-7-13 2015-12-03
Novel polypeptides 2014-10-29 2014-12-10
Methods and compositions 2014-7-23 2015-6-18
Novel polypeptides 2014-6-10 2014-7-23
Ligand drug conjugates 2014-5-08 2014-6-25
Structured peptide processing 2014-4-01 2017-5-09 2017-5-09
Novel polypeptides 2013-10-28 2013-12-11
Structured polypeptides with sarcosine linkers 2012-10-08 2013-7-04
Modulation of structured polypeptide specificity 2012-3-29 2012-5-16
Modulation of structure polypeptide specificity 2011-10-07 2011-11-23